Cargando…

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic

The β-lactam antibiotic temocillin (6-α-methoxy-ticarcillin) shows stability to most extended spectrum β-lactamases, but is considered inactive against Pseudomonas aeruginosa. Mutations in the MexAB-OprM efflux system, naturally occurring in cystic fibrosis (CF) isolates, have been previously shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalhoub, Hussein, Pletzer, Daniel, Weingart, Helge, Braun, Yvonne, Tunney, Michael M., Elborn, J. Stuart, Rodriguez-Villalobos, Hector, Plésiat, Patrick, Kahl, Barbara C., Denis, Olivier, Winterhalter, Mathias, Tulkens, Paul M., Van Bambeke, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238406/
https://www.ncbi.nlm.nih.gov/pubmed/28091521
http://dx.doi.org/10.1038/srep40208
_version_ 1782495700167163904
author Chalhoub, Hussein
Pletzer, Daniel
Weingart, Helge
Braun, Yvonne
Tunney, Michael M.
Elborn, J. Stuart
Rodriguez-Villalobos, Hector
Plésiat, Patrick
Kahl, Barbara C.
Denis, Olivier
Winterhalter, Mathias
Tulkens, Paul M.
Van Bambeke, Françoise
author_facet Chalhoub, Hussein
Pletzer, Daniel
Weingart, Helge
Braun, Yvonne
Tunney, Michael M.
Elborn, J. Stuart
Rodriguez-Villalobos, Hector
Plésiat, Patrick
Kahl, Barbara C.
Denis, Olivier
Winterhalter, Mathias
Tulkens, Paul M.
Van Bambeke, Françoise
author_sort Chalhoub, Hussein
collection PubMed
description The β-lactam antibiotic temocillin (6-α-methoxy-ticarcillin) shows stability to most extended spectrum β-lactamases, but is considered inactive against Pseudomonas aeruginosa. Mutations in the MexAB-OprM efflux system, naturally occurring in cystic fibrosis (CF) isolates, have been previously shown to reverse this intrinsic resistance. In the present study, we measured temocillin activity in a large collection (n = 333) of P. aeruginosa CF isolates. 29% of the isolates had MICs ≤ 16 mg/L (proposed clinical breakpoint for temocillin). Mutations were observed in mexA or mexB in isolates for which temocillin MIC was ≤512 mg/L (nucleotide insertions or deletions, premature termination, tandem repeat, nonstop, and missense mutations). A correlation was observed between temocillin MICs and efflux rate of N-phenyl-1-naphthylamine (MexAB-OprM fluorescent substrate) and extracellular exopolysaccharide abundance (contributing to a mucoid phenotype). OpdK or OpdF anion-specific porins expression decreased temocillin MIC by ~1 two-fold dilution only. Contrarily to the common assumption that temocillin is inactive on P. aeruginosa, we show here clinically-exploitable MICs on a non-negligible proportion of CF isolates, explained by a wide diversity of mutations in mexA and/or mexB. In a broader context, this work contributes to increase our understanding of MexAB-OprM functionality and help delineating how antibiotics interact with MexA and MexB.
format Online
Article
Text
id pubmed-5238406
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52384062017-01-19 Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic Chalhoub, Hussein Pletzer, Daniel Weingart, Helge Braun, Yvonne Tunney, Michael M. Elborn, J. Stuart Rodriguez-Villalobos, Hector Plésiat, Patrick Kahl, Barbara C. Denis, Olivier Winterhalter, Mathias Tulkens, Paul M. Van Bambeke, Françoise Sci Rep Article The β-lactam antibiotic temocillin (6-α-methoxy-ticarcillin) shows stability to most extended spectrum β-lactamases, but is considered inactive against Pseudomonas aeruginosa. Mutations in the MexAB-OprM efflux system, naturally occurring in cystic fibrosis (CF) isolates, have been previously shown to reverse this intrinsic resistance. In the present study, we measured temocillin activity in a large collection (n = 333) of P. aeruginosa CF isolates. 29% of the isolates had MICs ≤ 16 mg/L (proposed clinical breakpoint for temocillin). Mutations were observed in mexA or mexB in isolates for which temocillin MIC was ≤512 mg/L (nucleotide insertions or deletions, premature termination, tandem repeat, nonstop, and missense mutations). A correlation was observed between temocillin MICs and efflux rate of N-phenyl-1-naphthylamine (MexAB-OprM fluorescent substrate) and extracellular exopolysaccharide abundance (contributing to a mucoid phenotype). OpdK or OpdF anion-specific porins expression decreased temocillin MIC by ~1 two-fold dilution only. Contrarily to the common assumption that temocillin is inactive on P. aeruginosa, we show here clinically-exploitable MICs on a non-negligible proportion of CF isolates, explained by a wide diversity of mutations in mexA and/or mexB. In a broader context, this work contributes to increase our understanding of MexAB-OprM functionality and help delineating how antibiotics interact with MexA and MexB. Nature Publishing Group 2017-01-16 /pmc/articles/PMC5238406/ /pubmed/28091521 http://dx.doi.org/10.1038/srep40208 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Chalhoub, Hussein
Pletzer, Daniel
Weingart, Helge
Braun, Yvonne
Tunney, Michael M.
Elborn, J. Stuart
Rodriguez-Villalobos, Hector
Plésiat, Patrick
Kahl, Barbara C.
Denis, Olivier
Winterhalter, Mathias
Tulkens, Paul M.
Van Bambeke, Françoise
Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title_full Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title_fullStr Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title_full_unstemmed Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title_short Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
title_sort mechanisms of intrinsic resistance and acquired susceptibility of pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238406/
https://www.ncbi.nlm.nih.gov/pubmed/28091521
http://dx.doi.org/10.1038/srep40208
work_keys_str_mv AT chalhoubhussein mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT pletzerdaniel mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT weingarthelge mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT braunyvonne mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT tunneymichaelm mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT elbornjstuart mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT rodriguezvillaloboshector mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT plesiatpatrick mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT kahlbarbarac mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT denisolivier mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT winterhaltermathias mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT tulkenspaulm mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic
AT vanbambekefrancoise mechanismsofintrinsicresistanceandacquiredsusceptibilityofpseudomonasaeruginosaisolatedfromcysticfibrosispatientstotemocillinarevivedantibiotic